Covered recipient · General Payments record
ANGELA YEN MOORE
Allopathic & Osteopathic Physicians Dermatology Dermatopathology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$115,344.28
308 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $88,225.23 | 29 |
| Consulting Fee | $11,740.00 | 5 |
| Food and Beverage | $7,662.86 | 232 |
| Travel and Lodging | $7,604.15 | 39 |
| Education | $112.04 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie, Inc. | $48,477.55 | 74 |
| Almirall LLC | $39,241.47 | 42 |
| Aclaris Therapeutics, Inc. | $6,733.77 | 9 |
| Biofrontera Inc. | $6,143.44 | 9 |
| LEO Pharma AS | $4,499.01 | 9 |
| PFIZER INC. | $3,141.45 | 11 |
| E.R. Squibb & Sons, L.L.C. | $2,381.97 | 5 |
| Galderma Laboratories, L.P. | $2,167.25 | 2 |
| Mayne Pharma Inc. | $777.09 | 92 |
| Novartis Pharmaceuticals Corporation | $391.16 | 8 |
| Lilly USA, LLC | $258.37 | 7 |
| Celgene Corporation | $230.17 | 2 |
| LEO Pharma Inc. | $211.89 | 14 |
| Janssen Biotech, Inc. | $178.20 | 9 |
| Sun Pharmaceutical Industries Inc. | $174.07 | 3 |
| UCB, Inc. | $100.52 | 1 |
| DERMIRA, INC. | $57.75 | 3 |
| Encore Dermatology Inc. | $47.42 | 3 |
| Allergan Inc. | $36.98 | 1 |
| Sandoz Inc. | $25.70 | 1 |
| Janssen Research & Development, LLC | $25.41 | 1 |
| Promius Pharma LLC | $22.78 | 1 |
| DUSA Pharmaceuticals, Inc. | $20.86 | 1 |
Page 6 of 7; records 251–300 of 308 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ANGELA YEN MOORE
NPI 1235142266 · CMS profile ID 328697
Allopathic & Osteopathic Physicians / Dermatology / Dermatopathology
ARLINGTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 7; records 251–300 of 308 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1235142266?year=2019&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ANGELA YEN MOORE, NPI 1235142266, CMS profile ID 328697. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 308 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235142266?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). ANGELA YEN MOORE, NPI 1235142266, CMS profile ID 328697. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 308 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235142266?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- ANGELA YEN MOORE, NPI 1235142266, CMS profile ID 328697, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 7; records 251–300 of 308 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1235142266?year=2019&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
308 matching records · $115,344.28 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–300 of 308.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie, Inc. | $119.70 | 03/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647827283 | CMS |
| Almirall LLC | $58.43 | 03/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665521 | CMS |
| Celgene Corporation | $97.85 | 03/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672749223 | CMS |
| Lilly USA, LLC | $24.50 | 03/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657691285 | CMS |
| PFIZER INC. | $46.27 | 03/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672124773 | CMS |
| Biofrontera Inc. | $39.55 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 667996929 | CMS |
| AbbVie, Inc. | $118.20 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647827319 | CMS |
| E.R. Squibb & Sons, L.L.C. | $124.74 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651439963 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.16 | 02/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651439965 | CMS |
| Mayne Pharma Inc. | $13.20 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705510363 | CMS |
| Mayne Pharma Inc. | $1.71 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705510365 | CMS |
| Mayne Pharma Inc. | $2.53 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705510369 | CMS |
| Mayne Pharma Inc. | $13.17 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705510371 | CMS |
| AbbVie, Inc. | $23.21 | 02/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647827285 | CMS |
| Almirall LLC | $18.40 | 02/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665505 | CMS |
| Almirall LLC | $24.94 | 02/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665489 | CMS |
| Almirall LLC | $52.45 | 02/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665494 | CMS |
| Almirall LLC | $149.29 | 02/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665481 | CMS |
| Almirall LLC | $27.26 | 02/20/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665485 | CMS |
| Janssen Biotech, Inc. | $22.07 | 02/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658603063 | CMS |
| Aclaris Therapeutics, Inc. | $500.00 | 02/19/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700983529 | CMS |
| Biofrontera Inc. | $83.19 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 667996587 | CMS |
| Mayne Pharma Inc. | $12.55 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705510359 | CMS |
| Mayne Pharma Inc. | $16.14 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705510353 | CMS |
| Mayne Pharma Inc. | $2.96 | 02/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705510357 | CMS |
| Promius Pharma LLC | $22.78 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701093027 | CMS |
| Almirall LLC | $103.14 | 02/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665477 | CMS |
| Almirall LLC | $16.82 | 02/07/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665473 | CMS |
| Almirall LLC | $112.38 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665461 | CMS |
| Almirall LLC | $24.36 | 02/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665469 | CMS |
| Janssen Biotech, Inc. | $1.54 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658603014 | CMS |
| Mayne Pharma Inc. | $18.97 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705510351 | CMS |
| Almirall LLC | $132.32 | 02/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665445 | CMS |
| Almirall LLC | $22.62 | 02/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665447 | CMS |
| Almirall LLC | $48.80 | 02/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665437 | CMS |
| Almirall LLC | $20.88 | 02/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665441 | CMS |
| LEO Pharma Inc. | $18.90 | 01/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 687267715 | CMS |
| Mayne Pharma Inc. | $6.13 | 01/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705510347 | CMS |
| Novartis Pharmaceuticals Corporation | $92.14 | 01/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659769833 | CMS |
| Mayne Pharma Inc. | $20.00 | 01/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705510343 | CMS |
| Mayne Pharma Inc. | $1.55 | 01/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705510345 | CMS |
| AbbVie, Inc. | $22.64 | 01/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647827281 | CMS |
| Almirall LLC | $119.40 | 01/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665429 | CMS |
| Mayne Pharma Inc. | $2.77 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705510337 | CMS |
| Mayne Pharma Inc. | $9.08 | 01/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705510339 | CMS |
| Almirall LLC | $25.23 | 01/21/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665407 | CMS |
| Almirall LLC | $5,000.00 | 01/21/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 676665411 | CMS |
| AbbVie, Inc. | $2,875.00 | 01/16/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647827275 | CMS |
| Mayne Pharma Inc. | $13.67 | 01/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705510335 | CMS |
| AbbVie, Inc. | $40.44 | 01/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647827277 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,778,173.66 | 254 |
| PY2024 | Principal investigator | $2,059,458.30 | 319 |
| PY2023 | Principal investigator | $1,094,340.18 | 232 |
| PY2022 | Principal investigator | $1,164,547.07 | 178 |
| PY2021 | Recipient | $27,537.00 | 2 |
| PY2021 | Principal investigator | $1,089,255.21 | 188 |
| PY2020 | Principal investigator | $700,899.48 | 135 |
| PY2019 | Recipient | $11,250.00 | 1 |
| PY2019 | Principal investigator | $1,162,550.93 | 139 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
254 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $1,529.40 | 12/31/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata | No dispute reported | 06/30/2026 | 1202534603 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,650.00 | 12/29/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175344862 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,094.00 | 12/25/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344822 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,229.00 | 12/25/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344891 |
| Principal investigator 1 | PFIZER INC. | $5,893.13 | 12/25/2025 | Non-covered Recipient Entity Arlington Research Center | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228743685 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,762.00 | 12/22/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area | No dispute reported | 06/30/2026 | 1175344936 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,357.20 | 12/22/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226103653 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,093.00 | 12/19/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344746 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $3,366.25 | 12/18/2025 | Non-covered Recipient Entity Arlington Research Center INC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430826 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $127.40 | 12/17/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223289872 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,286.00 | 12/15/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344664 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,000.50 | 12/15/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344755 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,778.00 | 12/15/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344799 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,000.00 | 12/15/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344817 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $31,208.00 | 12/15/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226103659 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $51,443.60 | 12/10/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289494 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,755.00 | 12/10/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289506 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,800.00 | 12/10/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289508 |
| Principal investigator 1 | ABBVIE INC. | $6,568.75 | 12/04/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202529126 |
| Principal investigator 1 | ABBVIE INC. | $1,832.25 | 12/04/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202529128 |
| Principal investigator 1 | ABBVIE INC. | $1,998.75 | 12/04/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202529130 |
| Principal investigator 1 | ABBVIE INC. | $5,553.04 | 12/04/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202529132 |
| Principal investigator 1 | ABBVIE INC. | $4,213.75 | 12/04/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202529134 |
| Principal investigator 1 | Incyte Corporation | $9.54 | 12/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503479 |
| Principal investigator 1 | Incyte Corporation | $47.40 | 12/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503490 |
| Principal investigator 1 | Incyte Corporation | $14.22 | 12/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503494 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 12/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503498 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 12/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503503 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 12/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503507 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 12/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503509 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503514 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503518 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,916.00 | 12/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344764 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,123.00 | 12/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344772 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,244.90 | 12/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289071 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,000.00 | 11/26/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175274936 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,071.00 | 11/26/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175275161 |
| Principal investigator 1 | Eli Lilly and Company | $25,884.00 | 11/24/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1187876467 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,897.50 | 11/24/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226103647 |
| Principal investigator 1 | PFIZER INC. | $1,843.75 | 11/18/2025 | Non-covered Recipient Entity Arlington Research Center | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228727215 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,229.00 | 11/17/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Efficacy Safety and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants | No dispute reported | 06/30/2026 | 1175344908 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $33,251.00 | 11/17/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226103641 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,122.50 | 11/13/2025 | Non-covered Recipient Entity Arlington Research Center INC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430824 |
| Principal investigator 1 | ABBVIE INC. | $2,400.00 | 11/06/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202523359 |
| Principal investigator 1 | ABBVIE INC. | $2,353.75 | 11/05/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202522247 |
| Principal investigator 1 | ABBVIE INC. | $7,944.01 | 11/05/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202522327 |
| Principal investigator 1 | ABBVIE INC. | $4,193.26 | 11/05/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202522329 |
| Principal investigator 1 | ABBVIE INC. | $3,289.00 | 11/04/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | No dispute reported | 06/30/2026 | 1202520575 |
| Principal investigator 1 | ABBVIE INC. | $27,688.75 | 11/04/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202520577 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,651.00 | 11/03/2025 | Non-covered Recipient Entity Arlington Research Center | VELARITE | No dispute reported | 06/30/2026 | 1211573619 |
| Principal investigator 1 | Incyte Corporation | $137.40 | 11/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503482 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 11/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503486 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $31,682.30 | 11/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287867 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,720.00 | 10/31/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344930 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $61.29 | 10/30/2025 | Non-covered Recipient Entity Arlington Center For Dermatology | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) | No dispute reported | 06/30/2026 | 1235998920 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $59,276.68 | 10/28/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1190307239 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,762.00 | 10/27/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344608 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,894.00 | 10/24/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344558 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2,670.63 | 10/23/2025 | Non-covered Recipient Entity Arlington Research Center INC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430820 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $10,402.51 | 10/23/2025 | Non-covered Recipient Entity Arlington Research Center INC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430822 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,835.80 | 10/14/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226103635 |
| Principal investigator 1 | PFIZER INC. | $4,386.88 | 10/11/2025 | Non-covered Recipient Entity Arlington Research Center | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228741182 |
| Principal investigator 1 | ABBVIE INC. | $4,002.88 | 10/09/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202515787 |
| Principal investigator 1 | ABBVIE INC. | $41.25 | 10/09/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202515789 |
| Principal investigator 1 | ABBVIE INC. | $2,096.63 | 10/09/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202515791 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $4,459.38 | 10/09/2025 | Non-covered Recipient Entity Arlington Research Center INC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430818 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $31,360.87 | 10/08/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190307241 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,421.80 | 10/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223286319 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,130.00 | 10/02/2025 | Non-covered Recipient Entity Arlington Research Center | VELARITE | No dispute reported | 06/30/2026 | 1211573610 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,496.00 | 10/02/2025 | Non-covered Recipient Entity Arlington Research Center | VELARITE | No dispute reported | 06/30/2026 | 1211573614 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,399.00 | 09/29/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344688 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,317.00 | 09/29/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175344700 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,243.00 | 09/29/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175344830 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $170,757.00 | 09/29/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226103619 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,420.00 | 09/22/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344922 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $15,000.00 | 09/22/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226103615 |
| Principal investigator 1 | Incyte Corporation | $1,924.20 | 09/10/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503475 |
| Principal investigator 1 | PFIZER INC. | $7,000.00 | 09/10/2025 | Non-covered Recipient Entity Arlington Research Center | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228723054 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,458.00 | 09/08/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344599 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,243.00 | 09/08/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175344789 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,102.50 | 09/08/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226103609 |
| Principal investigator 1 | ABBVIE INC. | $1,931.25 | 09/04/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202509236 |
| Principal investigator 1 | ABBVIE INC. | $7,602.50 | 09/04/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202509250 |
| Principal investigator 1 | ABBVIE INC. | $11,823.39 | 09/04/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202509252 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,813.00 | 09/04/2025 | Non-covered Recipient Entity Arlington Research Center | VELARITE | No dispute reported | 06/30/2026 | 1211573593 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,018.00 | 09/04/2025 | Non-covered Recipient Entity Arlington Research Center | VELARITE | No dispute reported | 06/30/2026 | 1211573598 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,251.00 | 09/04/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344679 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,130.00 | 09/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344715 |
| Principal investigator 1 | Janssen Research & Development, LLC | $864.00 | 08/29/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175344915 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,165.00 | 08/29/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175344958 |
| Principal investigator 1 | ABBVIE INC. | $1,750.00 | 08/25/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | No dispute reported | 06/30/2026 | 1202505669 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,548.80 | 08/22/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284523 |
| Principal investigator 1 | Biofrontera Inc. | $425.00 | 08/15/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A SINGLE CENTER, OPEN-LABEL, PROSPECTIVE STUDY ON THE EFFICACY AND SAFETY OF PHOTODYNAMIC THERAPY WITH AMINOLEVULINIC ACID HYDROCHLORIDE 10% GEL (ALA GEL) FOR ADULT SUBJECTS WITH ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1208907583 |
| Principal investigator 1 | SUN PHARMACEUTICAL INDUSTRIES INC. | $5,400.01 | 08/13/2025 | Non-covered Recipient Entity Arlington Research Center INC | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis | No dispute reported | 06/30/2026 | 1246430816 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,334.83 | 08/13/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223284209 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,980.50 | 08/11/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226103603 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,597.00 | 08/08/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175344949 |
| Principal investigator 1 | ABBVIE INC. | $16,193.75 | 08/06/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202502470 |
| Principal investigator 1 | ABBVIE INC. | $11,885.13 | 08/06/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202502472 |
| Principal investigator 1 | ABBVIE INC. | $3,862.50 | 08/06/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202502532 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 08/06/2025 | Non-covered Recipient Entity PROGRESSIVE CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240577751 |
| Principal investigator 1 | Incyte Corporation | $9.72 | 08/06/2025 | Non-covered Recipient Entity PROGRESSIVE CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240577760 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 08/06/2025 | Non-covered Recipient Entity PROGRESSIVE CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240577766 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 08/06/2025 | Non-covered Recipient Entity PROGRESSIVE CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240577773 |
| Principal investigator 1 | Incyte Corporation | $0.62 | 08/06/2025 | Non-covered Recipient Entity PROGRESSIVE CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240577777 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 08/06/2025 | Non-covered Recipient Entity PROGRESSIVE CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240577783 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 08/06/2025 | Non-covered Recipient Entity PROGRESSIVE CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240577789 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 08/06/2025 | Non-covered Recipient Entity PROGRESSIVE CLINICAL RESEARCH | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240577795 |
| Principal investigator 1 | ABBVIE INC. | $294.75 | 08/05/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202501342 |
| Principal investigator 1 | ABBVIE INC. | $1,542.00 | 08/05/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202501344 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $1,863.00 | 08/01/2025 | Non-covered Recipient Entity Arlington Research Center | VELARITE | No dispute reported | 06/30/2026 | 1211573606 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,639.00 | 08/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283747 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,925.10 | 08/01/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223283749 |
| Principal investigator 1 | ABBVIE INC. | $7,700.00 | 07/29/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202500364 |
| Principal investigator 1 | ABBVIE INC. | $2,400.00 | 07/29/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202500372 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,704.00 | 07/28/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344654 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,503.00 | 07/28/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344848 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,861.90 | 07/14/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226103589 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,000.00 | 07/10/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175344810 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,881.00 | 07/10/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175344869 |
| Principal investigator 1 | Incyte Corporation | $1,346.40 | 07/09/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503471 |
| Principal investigator 1 | PFIZER INC. | $13,440.00 | 07/09/2025 | Non-covered Recipient Entity Arlington Research Center | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228720231 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,663.90 | 07/09/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223282426 |
| Principal investigator 1 | ABBVIE INC. | $11,015.75 | 07/08/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202497320 |
| Principal investigator 1 | ABBVIE INC. | $6,971.63 | 07/08/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202497342 |
| Principal investigator 1 | ABBVIE INC. | $4,303.75 | 07/02/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202495753 |
| Principal investigator 1 | ABBVIE INC. | $11,552.50 | 07/02/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202495755 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $3,510.07 | 07/02/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata | No dispute reported | 06/30/2026 | 1248163696 |
| Principal investigator 1 | Hoffmann-La Roche Limited | $2,500.00 | 07/02/2025 | Non-covered Recipient Entity Arlington Research Center | VELARITE | No dispute reported | 06/30/2026 | 1211573602 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,819.00 | 07/02/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226103595 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,596.00 | 06/30/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344634 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,567.00 | 06/30/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175344642 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,710.00 | 06/26/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344885 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,633.00 | 06/23/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344583 |
| Principal investigator 1 | Genentech, Inc. | $1,968.00 | 06/18/2025 | Non-covered Recipient Entity Arlington Research Center | VELARITE | No dispute reported | 06/30/2026 | 1211573569 |
| Principal investigator 1 | Genentech, Inc. | $2,130.00 | 06/18/2025 | Non-covered Recipient Entity Arlington Research Center | VELARITE | No dispute reported | 06/30/2026 | 1211573573 |
| Principal investigator 1 | Genentech, Inc. | $1,813.00 | 06/18/2025 | Non-covered Recipient Entity Arlington Research Center | VELARITE | No dispute reported | 06/30/2026 | 1211573581 |
| Principal investigator 1 | Genentech, Inc. | $1,623.00 | 06/18/2025 | Non-covered Recipient Entity Arlington Research Center | VELARITE | No dispute reported | 06/30/2026 | 1211573585 |
| Principal investigator 1 | Genentech, Inc. | $2,496.00 | 06/18/2025 | Non-covered Recipient Entity Arlington Research Center | VELARITE | No dispute reported | 06/30/2026 | 1211573589 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,805.00 | 06/13/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175275002 |
| Principal investigator 1 | Incyte Corporation | $1,346.40 | 06/11/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503450 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,881.00 | 06/09/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175344780 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,181.95 | 06/06/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280928 |
| Principal investigator 1 | ABBVIE INC. | $10,991.26 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202489419 |
| Principal investigator 1 | ABBVIE INC. | $6,342.00 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202489653 |
| Principal investigator 1 | ABBVIE INC. | $8,208.75 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202489655 |
| Principal investigator 1 | ABBVIE INC. | $1,347.50 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202489657 |
| Principal investigator 1 | ABBVIE INC. | $312.25 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202489659 |
| Principal investigator 1 | ABBVIE INC. | $1,789.75 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202489661 |
| Principal investigator 1 | Incyte Corporation | $12.36 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503400 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503407 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503414 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503419 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503423 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503427 |
| Principal investigator 1 | Incyte Corporation | $14.84 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503433 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503438 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503444 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503454 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503459 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503463 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 06/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503467 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,950.00 | 05/26/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344856 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,978.31 | 05/23/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280302 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,508.00 | 05/22/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344737 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,000.00 | 05/19/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344647 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,919.20 | 05/19/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) | No dispute reported | 06/30/2026 | 1226103582 |
| Principal investigator 1 | Genentech, Inc. | $3,000.00 | 05/14/2025 | Non-covered Recipient Entity Arlington Research Center | VELARITE | No dispute reported | 06/30/2026 | 1211573577 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 05/14/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223279758 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,664.00 | 05/09/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175344901 |
| Principal investigator 1 | ABBVIE INC. | $11,435.25 | 05/07/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202482475 |
| Principal investigator 1 | ABBVIE INC. | $6,707.63 | 05/07/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202482477 |
| Principal investigator 1 | ABBVIE INC. | $20,127.50 | 05/07/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202483213 |
| Principal investigator 1 | ABBVIE INC. | $5,576.25 | 05/06/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202481229 |
| Principal investigator 1 | ABBVIE INC. | $1,263.50 | 05/06/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202481717 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $32,387.50 | 05/05/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226103578 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,995.00 | 04/28/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175275013 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,934.00 | 04/28/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175275081 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,168.00 | 04/28/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344730 |
| Principal investigator 1 | Incyte Corporation | $1,700.00 | 04/25/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) | No dispute reported | 06/30/2026 | 1240503395 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,925.20 | 04/11/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278024 |
| Principal investigator 1 | Incyte Corporation | $1,346.40 | 04/09/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503411 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,046.06 | 04/09/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277734 |
| Principal investigator 1 | ABBVIE INC. | $4,118.25 | 04/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202470673 |
| Principal investigator 1 | ABBVIE INC. | $14,665.00 | 04/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202470677 |
| Principal investigator 1 | ABBVIE INC. | $2,116.25 | 04/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202470682 |
| Principal investigator 1 | ABBVIE INC. | $4,921.25 | 04/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202470685 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,664.00 | 03/31/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175344577 |
| Principal investigator 1 | Incyte Corporation | $133.06 | 03/27/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240503391 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,190.00 | 03/27/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344592 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,976.00 | 03/24/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344723 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,610.00 | 03/21/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175274956 |
| Principal investigator 1 | UCB SA | $26,770.00 | 03/21/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB COMPARED TO USTEKINUMAB IN CHILDREN AND ADOLESCENTS FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH MODERATE TO SEVERE PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 1246656306 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $21,379.80 | 03/17/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226103567 |
| Principal investigator 1 | Incyte Corporation | $1,346.40 | 03/12/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503359 |
| Principal investigator 1 | ABBVIE INC. | $7,320.00 | 03/07/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202460415 |
| Principal investigator 1 | ABBVIE INC. | $9,806.75 | 03/07/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202460563 |
| Principal investigator 1 | ABBVIE INC. | $7,458.75 | 03/07/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202460567 |
| Principal investigator 1 | ABBVIE INC. | $1,263.50 | 03/06/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202457686 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,972.72 | 03/05/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223276017 |
| Principal investigator 1 | Incyte Corporation | $9.72 | 03/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503363 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 03/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503371 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 03/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503380 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,334.00 | 03/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344618 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,887.00 | 03/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344669 |
| Principal investigator 1 | UCB SA | $2,190.60 | 03/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | No dispute reported | 06/30/2026 | 1246659561 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,995.00 | 02/27/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175275072 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,995.00 | 02/27/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175275089 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,589.00 | 02/27/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175275148 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,995.00 | 02/27/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175275173 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $18,099.90 | 02/26/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275629 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $53,769.30 | 02/18/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226103559 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 02/07/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175275110 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,744.00 | 02/07/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175275133 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,500.00 | 02/07/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175275140 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,766.00 | 02/07/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175275189 |
| Principal investigator 1 | ABBVIE INC. | $27,721.25 | 02/06/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202447291 |
| Principal investigator 1 | ABBVIE INC. | $8,318.75 | 02/06/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) | No dispute reported | 06/30/2026 | 1202447341 |
| Principal investigator 1 | ABBVIE INC. | $11,692.00 | 02/06/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) | No dispute reported | 06/30/2026 | 1202447347 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,071.00 | 02/06/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175274963 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,395.00 | 02/06/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175275022 |
| Principal investigator 1 | ABBVIE INC. | $312.25 | 02/05/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202444238 |
| Principal investigator 1 | ABBVIE INC. | $294.75 | 02/05/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202445333 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $22,617.11 | 02/05/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274843 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,371.00 | 01/31/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175344944 |
| Principal investigator 1 | UCB SA | $13,836.00 | 01/31/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa | No dispute reported | 06/30/2026 | 1246657089 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 01/29/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175275096 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 01/29/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175275104 |
| Principal investigator 1 | Janssen Research & Development, LLC | $254.00 | 01/29/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175275204 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,678.00 | 01/27/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) | No dispute reported | 06/30/2026 | 1175275181 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,032.00 | 01/27/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175344838 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,491.00 | 01/24/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment | No dispute reported | 06/30/2026 | 1175344568 |
| Principal investigator 1 | Incyte Corporation | $5,670.91 | 01/23/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 1240503388 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,800.00 | 01/22/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223274367 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $48,967.00 | 01/21/2025 | Non-covered Recipient Entity Arlington Research Center Inc | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226103573 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,508.00 | 01/17/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175344708 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,271.00 | 01/17/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175344876 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,105.00 | 01/16/2025 | Non-covered Recipient Entity Arlington Rsrch Ctr | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) | No dispute reported | 06/30/2026 | 1175275048 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,000.00 | 01/16/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf | No dispute reported | 06/30/2026 | 1175344626 |
| Principal investigator 1 | Incyte Corporation | $1,472.40 | 01/15/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503351 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 01/08/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273795 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $755.00 | 01/08/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273797 |
| Principal investigator 1 | Biofrontera Inc. | $11,174.83 | 01/06/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A SINGLE CENTER, OPEN-LABEL, PROSPECTIVE STUDY ON THE EFFICACY AND SAFETY OF PHOTODYNAMIC THERAPY WITH AMINOLEVULINIC ACID HYDROCHLORIDE 10% GEL (ALA GEL) FOR ADULT SUBJECTS WITH ONYCHOMYCOSIS | No dispute reported | 06/30/2026 | 1208907239 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 01/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273535 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 01/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273537 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,700.00 | 01/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273539 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,000.00 | 01/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273541 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 01/03/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223273543 |
| Principal investigator 1 | ABBVIE INC. | $1,458.00 | 01/02/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202433925 |
| Principal investigator 1 | ABBVIE INC. | $1,832.25 | 01/02/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER INC | M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) | No dispute reported | 06/30/2026 | 1202435193 |
| Principal investigator 1 | Incyte Corporation | $201.40 | 01/02/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503355 |
| Principal investigator 1 | Incyte Corporation | $68.90 | 01/02/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503367 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503376 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 01/02/2025 | Non-covered Recipient Entity ARLINGTON RESEARCH CENTER | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240503383 |